Cargando…
Performance of Controlled Attenuation Parameter in Patients with Advanced Chronic Liver Disease and Portal Hypertension
BACKGROUND: Liver stiffness (LS) measured by vibration-controlled transient elastography (VCTE) is influenced by liver fibrosis and hepatic perfusion pressure. VCTE-based controlled attenuation parameter (CAP) is a noninvasive marker for hepatic steatosis (HS). AIMS: To investigate the diagnostic pe...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6858384/ https://www.ncbi.nlm.nih.gov/pubmed/31209721 http://dx.doi.org/10.1007/s10620-019-05702-7 |
_version_ | 1783470948064690176 |
---|---|
author | Semmler, Georg Stift, Judith Scheiner, Bernhard Wöran, Katharina Schwabl, Philipp Paternostro, Rafael Bucsics, Theresa Stättermayer, Albert Friedrich Pinter, Matthias Ferlitsch, Arnulf Trauner, Michael Reiberger, Thomas Mandorfer, Mattias |
author_facet | Semmler, Georg Stift, Judith Scheiner, Bernhard Wöran, Katharina Schwabl, Philipp Paternostro, Rafael Bucsics, Theresa Stättermayer, Albert Friedrich Pinter, Matthias Ferlitsch, Arnulf Trauner, Michael Reiberger, Thomas Mandorfer, Mattias |
author_sort | Semmler, Georg |
collection | PubMed |
description | BACKGROUND: Liver stiffness (LS) measured by vibration-controlled transient elastography (VCTE) is influenced by liver fibrosis and hepatic perfusion pressure. VCTE-based controlled attenuation parameter (CAP) is a noninvasive marker for hepatic steatosis (HS). AIMS: To investigate the diagnostic performance of CAP in patients with advanced chronic liver disease (ACLD)/portal hypertension (PHT: hepatic venous pressure gradient (HVPG) ≥ 6 mmHg). METHODS: Eighty-eight patients with LS ≥ 10 kPa and/or HVPG ≥ 6 mmHg who underwent simultaneous liver biopsy, CAP, and HVPG measurement were included. HS was histologically graded according to the modified Brunt classification. RESULTS: Patient characteristics: Mean MELD:11 (standard derivation [SD] ± 4), median HVPG:16 (interquartile range [IQR]10–19) mmHg, median LS:27.4 (IQR 16.2–48.9) kPa, and mean CAP:221 (SD ± 75) dB/m. According to histology, 47 (53.4%) patients had no HS (S0), 28 (31.8%) had S1, 11 (12.5%) had S2, and 2 (2.3%) had S3. The area under the receiver operating characteristic curve (AUROC) of CAP for diagnosing any HS (S0 vs. ≥ S1) was 0.692 (95% confidence interval [95% CI] 0.582–0.802) in the overall cohort, 0.830 (95% CI 0.637–1.0) in patients with HVPG < 10 mmHg, and 0.629 (95% CI 0.497–0.761) in patients with clinically significant portal hypertension (CSPH; HVPG ≥ 10 mmHg; n = 69). Using the established cutoff for any HS (248 dB/m), the sensitivity/specificity of CAP was only 48.8%/76.6%, respectively. In contrast, the AUROC and sensitivity/specificity (cutoff 268 dB/m) for diagnosing HS ≥ S2 were 0.842 (95% CI 0.747–0.936) and 84.6%/81.3%, respectively. CAP correlated with the percentage of steatotic hepatocytes (Spearman’s ρ = 0.402; p ≤ 0.001) and showed a weak correlation with liver stiffness (ρ = 0.225; p = 0.035). CONCLUSIONS: The diagnostic performance of CAP for any HS seems to be limited in patients with ACLD, if CSPH is present. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s10620-019-05702-7) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-6858384 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Springer US |
record_format | MEDLINE/PubMed |
spelling | pubmed-68583842019-12-03 Performance of Controlled Attenuation Parameter in Patients with Advanced Chronic Liver Disease and Portal Hypertension Semmler, Georg Stift, Judith Scheiner, Bernhard Wöran, Katharina Schwabl, Philipp Paternostro, Rafael Bucsics, Theresa Stättermayer, Albert Friedrich Pinter, Matthias Ferlitsch, Arnulf Trauner, Michael Reiberger, Thomas Mandorfer, Mattias Dig Dis Sci Original Article BACKGROUND: Liver stiffness (LS) measured by vibration-controlled transient elastography (VCTE) is influenced by liver fibrosis and hepatic perfusion pressure. VCTE-based controlled attenuation parameter (CAP) is a noninvasive marker for hepatic steatosis (HS). AIMS: To investigate the diagnostic performance of CAP in patients with advanced chronic liver disease (ACLD)/portal hypertension (PHT: hepatic venous pressure gradient (HVPG) ≥ 6 mmHg). METHODS: Eighty-eight patients with LS ≥ 10 kPa and/or HVPG ≥ 6 mmHg who underwent simultaneous liver biopsy, CAP, and HVPG measurement were included. HS was histologically graded according to the modified Brunt classification. RESULTS: Patient characteristics: Mean MELD:11 (standard derivation [SD] ± 4), median HVPG:16 (interquartile range [IQR]10–19) mmHg, median LS:27.4 (IQR 16.2–48.9) kPa, and mean CAP:221 (SD ± 75) dB/m. According to histology, 47 (53.4%) patients had no HS (S0), 28 (31.8%) had S1, 11 (12.5%) had S2, and 2 (2.3%) had S3. The area under the receiver operating characteristic curve (AUROC) of CAP for diagnosing any HS (S0 vs. ≥ S1) was 0.692 (95% confidence interval [95% CI] 0.582–0.802) in the overall cohort, 0.830 (95% CI 0.637–1.0) in patients with HVPG < 10 mmHg, and 0.629 (95% CI 0.497–0.761) in patients with clinically significant portal hypertension (CSPH; HVPG ≥ 10 mmHg; n = 69). Using the established cutoff for any HS (248 dB/m), the sensitivity/specificity of CAP was only 48.8%/76.6%, respectively. In contrast, the AUROC and sensitivity/specificity (cutoff 268 dB/m) for diagnosing HS ≥ S2 were 0.842 (95% CI 0.747–0.936) and 84.6%/81.3%, respectively. CAP correlated with the percentage of steatotic hepatocytes (Spearman’s ρ = 0.402; p ≤ 0.001) and showed a weak correlation with liver stiffness (ρ = 0.225; p = 0.035). CONCLUSIONS: The diagnostic performance of CAP for any HS seems to be limited in patients with ACLD, if CSPH is present. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s10620-019-05702-7) contains supplementary material, which is available to authorized users. Springer US 2019-06-17 2019 /pmc/articles/PMC6858384/ /pubmed/31209721 http://dx.doi.org/10.1007/s10620-019-05702-7 Text en © The Author(s) 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Original Article Semmler, Georg Stift, Judith Scheiner, Bernhard Wöran, Katharina Schwabl, Philipp Paternostro, Rafael Bucsics, Theresa Stättermayer, Albert Friedrich Pinter, Matthias Ferlitsch, Arnulf Trauner, Michael Reiberger, Thomas Mandorfer, Mattias Performance of Controlled Attenuation Parameter in Patients with Advanced Chronic Liver Disease and Portal Hypertension |
title | Performance of Controlled Attenuation Parameter in Patients with Advanced Chronic Liver Disease and Portal Hypertension |
title_full | Performance of Controlled Attenuation Parameter in Patients with Advanced Chronic Liver Disease and Portal Hypertension |
title_fullStr | Performance of Controlled Attenuation Parameter in Patients with Advanced Chronic Liver Disease and Portal Hypertension |
title_full_unstemmed | Performance of Controlled Attenuation Parameter in Patients with Advanced Chronic Liver Disease and Portal Hypertension |
title_short | Performance of Controlled Attenuation Parameter in Patients with Advanced Chronic Liver Disease and Portal Hypertension |
title_sort | performance of controlled attenuation parameter in patients with advanced chronic liver disease and portal hypertension |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6858384/ https://www.ncbi.nlm.nih.gov/pubmed/31209721 http://dx.doi.org/10.1007/s10620-019-05702-7 |
work_keys_str_mv | AT semmlergeorg performanceofcontrolledattenuationparameterinpatientswithadvancedchronicliverdiseaseandportalhypertension AT stiftjudith performanceofcontrolledattenuationparameterinpatientswithadvancedchronicliverdiseaseandportalhypertension AT scheinerbernhard performanceofcontrolledattenuationparameterinpatientswithadvancedchronicliverdiseaseandportalhypertension AT worankatharina performanceofcontrolledattenuationparameterinpatientswithadvancedchronicliverdiseaseandportalhypertension AT schwablphilipp performanceofcontrolledattenuationparameterinpatientswithadvancedchronicliverdiseaseandportalhypertension AT paternostrorafael performanceofcontrolledattenuationparameterinpatientswithadvancedchronicliverdiseaseandportalhypertension AT bucsicstheresa performanceofcontrolledattenuationparameterinpatientswithadvancedchronicliverdiseaseandportalhypertension AT stattermayeralbertfriedrich performanceofcontrolledattenuationparameterinpatientswithadvancedchronicliverdiseaseandportalhypertension AT pintermatthias performanceofcontrolledattenuationparameterinpatientswithadvancedchronicliverdiseaseandportalhypertension AT ferlitscharnulf performanceofcontrolledattenuationparameterinpatientswithadvancedchronicliverdiseaseandportalhypertension AT traunermichael performanceofcontrolledattenuationparameterinpatientswithadvancedchronicliverdiseaseandportalhypertension AT reibergerthomas performanceofcontrolledattenuationparameterinpatientswithadvancedchronicliverdiseaseandportalhypertension AT mandorfermattias performanceofcontrolledattenuationparameterinpatientswithadvancedchronicliverdiseaseandportalhypertension |